Amended the original 10-K filing to include Part III information regarding directors, executive officers, and corporate governance. Reported a net loss of $2,680,860 for the fiscal year ended December 31, 2025, compared to a net loss of $3,960,275 in 2024. James Parslow serves as Interim CEO and CFO with a base salary of $400,000 and received a $100,000 retention bonus in 2025. Disclosed a $0.4 million consulting agreement with Board Chairman Dr. Dmitry Genkin for services related to the oncology program. Maintains a clinical trial services agreement with Peri-Ness Ltd, an entity affiliated with two directors, with estimated costs of $0.3 million. The aggregate market value of common stock held by non-affiliates was approximately $5,110,488 as of June 30, 2025.